Catalio Capital Management »

Incyte Corporation shares owned by Catalio Capital Management

Quarter-by-quarter ownership of Incyte Corporation (INCY) shares owned by Catalio Capital Management from 13F filings

Historical chart of Catalio Capital Management investment in Incyte Corporation

Tip: Access up to 7 years of quarterly data

All positions including Incyte Corporation held by Catalio Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Incyte Corporation by Catalio Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $17M 182k 94.12

More positions owned by Catalio Capital Management

Dianthus Therapeutics (DNTH)
Bridgebio Pharma (BBIO)
Ascendis Pharma A/s Sponsored Adr (ASND)
Bristol Myers Squibb (BMY)
Syndax Pharmaceuticals (SNDX)
Gilead Sciences (GILD)
Terns Pharmaceuticals (TERN)
Definium Therapeutics Com Shs (DFTX)
Soleno Therapeutics (SLNO)
Boston Scientific Corporation (BSX)
Ultragenyx Pharmaceutical (RARE)
Incyte Corporation (INCY)
Cytokinetics Com New (CYTK)
Natera (NTRA)
Corvus Pharmaceuticals (CRVS)

View all positions for Catalio Capital Management

Top funds holding Incyte Corporation

Baker Bros. Advisors
Vanguard Group
BlackRock
Dodge & Cox
Vanguard Capital Management
State Street Corporation
Vanguard Portfolio Management
AQR Capital Management
Geode Capital Management
Renaissance Technologies
LSV Asset Management
Invesco
Arrowstreet Capital, Limited Partnership
Morgan Stanley
Robeco Institutional Asset Management B V

View all funds holding Incyte Corporation